The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Research Funding - Celgene; MSD; Roche
Travel, Accommodations, Expenses - MSD; Pfizer; Roche
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Karl D. Lewis
Honoraria - Array BioPharma
Consulting or Advisory Role - Array BioPharma; Merck; Regeneron; Roche
Research Funding - alkermes (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Rodrigo Munhoz
No Relationships to Disclose
 
Gabriella Liszkay
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
Research Funding - Novartis; Roche
 
Luis De La Cruz Merino
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Pfizer; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Research Funding - Celgene; Merck; Roche
Travel, Accommodations, Expenses - MSD; Pfizer; Roche
 
Judit Olah
No Relationships to Disclose
 
Paola Queirolo
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
 
Jacek Mackiewicz
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Pierre Fabre; Roche
 
Haocheng Li
Employment - Roche Canada
 
Qian Zhu
Employment - Edwards Lifesciences
Stock and Other Ownership Interests - Edwards Lifesciences
Consulting or Advisory Role - Experis
 
V. McNally
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Edward Francis Mckenna
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Grant A. McArthur
Research Funding - Genentech (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); MSD (Inst); Roche (Inst)